- Ginkgo Bioworks Holdings Inc (NYSE:DNA) collaborated with Merck & Co Inc (NYSE:MRK) to engineer up to four enzymes for use as biocatalysts in Merck’s active pharmaceutical ingredient (API) manufacturing efforts.
- Through this collaboration, Ginkgo will leverage its experience in cell engineering and enzyme design and its capabilities in automated high throughput screening, manufacturing process development/optimization, bioinformatics, and analytics to deliver optimal strains for the expression of targeted biocatalysts.
- Also read: Cathie Wood Favorite Ginkgo Bioworks Bolsters Biosecurity Platform Via This Acquisition.
- Under the terms of the collaboration, Ginkgo will earn an upfront research and development fee and is eligible for success-based research and development milestone payments.
- In addition, Ginkgo is eligible to earn commercial milestone payments for each of a specified number of biocatalysis targets, which have the potential to total, in the aggregate, up to $144 million.
- Price Action: DNA shares are up 5.19% at $3.04 on the last check Tuesday.
Ambow Education Q2 EPS $(0.02) Up From $(0.05) YoY; Revenue $2.7M Down From $5M YoY
Second Quarter 2023 Financial HighlightsNet revenues for the second quarter of 2023 decreased by 46.0% to $2.7 million from $5.0 million for the same period of 2022. The decrease was primarily due to the permanent
